FDA releases 14 drug rejection letters after 3-month pause

The FDA has resumed publishing drug rejection letters (Complete Response Letters) after a three-month pause, releasing 14 letters dating back to April 2026. The transparency initiative, championed by former FDA Commissioner Marty Makary, faces legal challenge from an unnamed pharma company seeking tighter redaction and sponsor involvement in disclosure.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.